Physician profile
Michael Eugene Aronov
NPI 1306405188
$2,560.69
in general payments reported to CMS, 2019-2025
30 companies · $979 in 2025
The $979 reported for 2025 was more than what a typical Neurology (Psychiatry & Neurology) provider received nationally (typical 2025 total: $454).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $295 · 2021: $11.73 · 2022: $196 · 2023: $589 · 2024: $489 · 2025: $979.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $2,058.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $2,057.78 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Ucb, INC. | $505.73 | 2022-2025 | Briviact, Fintepla |
| Abbvie INC. | $279.39 | 2023-2025 | Ubrelvy, Qulipta, Botox |
| Neuropace, INC. | $253.10 | 2022-2023 | |
| Biogen, INC. | $174.90 | 2019-2025 | Tysabri, Skyclarys |
| Novartis Pharmaceuticals Corporation | $129.55 | 2023-2025 | |
| Greenwich Biosciences, INC. | $127.57 | 2019 | |
| Tg Therapeutics, INC. | $104.69 | 2024-2025 | |
| Takeda Pharmaceuticals U.S.A., INC. | $95.17 | 2025 | Hyqvia |
| Jazz Pharmaceuticals INC. | $76.44 | 2023 | |
| Teva Pharmaceuticals USA, INC. | $72.16 | 2019 | |
| Lilly USA, LLC | $60.04 | 2024-2025 | Kisunla, Emgality, Amyvid |
| Neurelis, INC. | $59.36 | 2024-2025 | Valtoco |
| Vanda Pharmaceuticals INC. | $57.28 | 2025 | Ponvory |
| Aucta Pharmaceuticals, INC. | $53.93 | 2024-2025 | Motpoly Xr |
| Otter Pharmaceuticals, LLC | $53.83 | 2025 | Sympazan |
Show all 30 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Sk Life Science, INC. | $51.07 | 2022-2025 | |
| Argenx US, INC. | $50.06 | 2025 | Vyvgart Hytrulo, Vyvgart |
| Eisai INC. | $48.39 | 2025 | |
| Tanabe Pharma America, INC. | $47.41 | 2024 | |
| Genentech USA, INC. | $45.22 | 2024-2025 | Ocrevus Zunovo, Enspryng, Ocrevus |
| Otsuka Pharmaceutical Development & Commercialization, INC. | $42.05 | 2024-2025 | Rexulti |
| Dexcom, INC. | $35.08 | 2024 | Dexcom G6 Transmitter |
| Lundbeck LLC | $22.81 | 2025 | Vyepti |
| Allergan, INC. | $21.70 | 2022 | |
| Hospira, INC. | $18.59 | 2024 | |
| E.R. Squibb & Sons, L.L.C. | $16.58 | 2022 | |
| Averitas Pharma INC. | $16.58 | 2025 | Qutenza |
| Otsuka America Pharmaceutical, INC. | $15.58 | 2023 | Nuedexta |
| Collegium Pharmaceutical, INC. | $14.70 | 2024 | Belbuca |
| Amneal Pharmaceuticals LLC | $11.73 | 2021 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Michael Aronov listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.